SANOFI’S OLD PROBLEMS IN WELCOMED NEW HANDS (REDUCE, 3% UPSIDE)
19/11/19 -"Days after we pitched for Sanofi (Reduce, France) in July 2019, the French pharma giant took an impairment charge of €1.8bn, mainly related to its c.€11bn acquisition of Bioverativ (haemophilia ..."
Pages
75
Language
English
Published on
19/11/19
You may also be interested by these reports :
26/04/24
The Q1 profits surpassed the street’s expectations, as all the three key molecules witnessed decent growth. Segment-wise, Spain and International ...
26/04/24
Hikma’s qualitative Q1 commentary entailed a positive tone for all the segments. Moreover, the management reaffirmed the full-year guidance. Since ...
25/04/24
The Q1 results topped expectations, led by robust performances across all the key segments. While the management maintained its 2024 guidance, an ...
25/04/24
Q1 results surpassed expectations, on the back of a strong showing from immunology drug Dupixent, RSV vaccine Beyfortus and the new launches of ...